Demonstrating the efficacy of your product is a vital stage in plant protection product development. It is a process that takes significant time, resource, and financial investment - from the design and implementation of efficacy trial programmes through to post trial efficacy data analysis and dossier authoring.

We understand the challenges faced throughout this journey, so we’re delighted to announce that with our partner ADAS, working together as part of the RSK Group, we have combined our expertise in efficacy testing and biological assessment dossier delivery to offer our clients a full end-to-end efficacy evaluation service, tailored to your exact needs.

Commission Regulation (EU) 2021/383 has been implemented by the European Union, which adds unacceptable co-formulants to Annex III of the EU PPP Regulation. The UK participated in extensive discussions as a Member State prior to this decision.

As a result of this regulation, PPPs and adjuvants with existing NI (Northern Ireland) authorizations that contain one or more of these co-formulants must be amended or withdrawn by 24 March 2023. The regulation specifies grace periods of 3 months for sale and distribution and an additional 9 months for disposal, storage and use after the date of amendment or withdrawal of the affected authorisations.

On 31st December 2020, the United Kingdom officially exited the European Union. As a result, all existing EU legislation, including that relating to chemicals, was adopted into UK law. These newly adopted laws are now applicable in Great Britain with special arrangements that have been made for Northern Ireland (NI), which remains subject to EU regulations. In this article, we focus on some of the impacts so far of EU exit on GB Plant Protection Products Regulation and GB Biocidal Products Regulation and where we have started seeing divergence in these regulations.